Skip to main content

Table 1 Characteristics of patients by experience with adverse event during DR-TB treatment (n = 149)

From: The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa

  Adverse event not reported (n = 91) Patient-reported adverse event (n = 58) Total (n = 149)
n (%) n (%) n (%)
Sex
 Male 47 (51.6%) 35 (60.3%) 82 (55.0%)
 Female 44 (48.4%) 23 (39.7%) 67 (45.0%)
Age at treatment initiation (years)
 Median (IQR) 36 (29–44) 35 (29–42) 36 (29–43)
 18–35 45 (49.5%) 29 (50%) 74 (49.7%)
  ≥ 35 46 (50.5%) 29 (50%) 75 (50.3%)
Education
 Secondary school and higher 86 (94.5%) 49 (84.5%) 135 (90.6%)
 Primary school or less 5 (5.5%) 9 (15.5%) 14 (9.4%)
Employment Status
 Unemployed 47 (51.6%) 38 (65.5%) 85 (57.0%)
 Employed 43 (47.3%) 20 (34.5%) 63 (42.3%)
 Missing/unknown 1 (1.1%) 0 (0%) 1 (0.7%)
Resistance Pattern
 MDR-TB (RIF and INH resistant) 22 (24.2%) 10 (17.2%) 32 (21.5%)
 RIF resistant by Xpert MTB/RIF 22 (24.2%) 16 (27.6%) 38 (25.5%)
 RIF mono-resistant (INH sensitive) 39 (42.9%) 28 (48.3%) 67 (45.0%)
 Missing 8 (8.8%) 4 (6.9%) 12 (8.1%)
HIV Status
 HIV negative 18 (19.8%) 9 (15.5%) 27 (18.1%)
 HIV positive 69 (75.8%) 47 (81.0%) 116 (77.9%)
 HIV positive and on ART 60 (87.0%) 34 (72.3%) 94 (81.0%)
 HIV positive not on ART 9 (13.0%) 13 (36.2%) 22 (19.0%)
 Unknown 4 (4.4%) 2 (3.5%) 6 (4.0%)
Baseline CD4 (cells/mm3)#
  < 50 23 (31.5%) 9 (18.4%) 32 (26.2%)
 51–250 21 (27.8%) 22 (44.9%) 43 (35.3%)
  > 250 22 (30.1%) 14 (28.6%) 36 (29.5%)
 Missing 7 (69.6%) 4 (8.2%) 11 (9.0%)
DR-TB regimen
 Standard long-coursea 61 (67.0%) 31 (53.4%) 92 (61.8%)
 Individualized long-courseb 17 (18.7%) 16 (27.6%) 33 (22.1%)
 Standard short-coursec 9 (9.9%) 6 (10.3%) 15 (10.1%)
 Individualized short-coursed 4 (4.4%) 5 (8.6%) 9 (6.0%)
Duration of DR-TB treatment (months)
  ≤ 6 months 37 (40.7%) 29 (50.0%) 66 (44.3%)
  > 6 months 54 (59.3%) 29 (50.0%) 83 (55.7%)
Duration of ART (months)&
  ≤ 6 months 9 (15.0%) 5 (14.7%) 14 (14.9%)
  > 6 months 44 (73.3%) 23 (67.6%) 67 (71.3%)
 Missing 7 (11.7%) 6 (17.6%) 13 (13.8%)
Diabetes
 No 67 (73.6%) 42 (72.4%) 109 (73.2%)
 Yes 4 (4.4%) 2 (3.5%) 6 (4.0%)
 Missing 20 (22.0%) 14 (24.1%) 34 (22.8%)
Anaemia
 None or mild (Hb ≥11.0 g/dL) 46 (50.5%) 18 (31.0%) 64 (43%)
 Moderate (8–10.9 g/dL) or severe (< 8 g/dL) 13 (14.3%) 13 (22.4%) 26 (17.4%)
 Missing 32 (35.2%) 27 (46.6%) 59 (39.6%)
Weight at treatment initiation (kg)
  < 50 kg 19 (20.9%) 18 (31.0%) 37 (24.8%)
  ≥ 50 kg 65 (71.4%) 38 (65.5%) 103 (69.1%)
 Missing 7 (7.7%) 2 (3.4%) 9 (6%)
Referring Facility
 Outpatient 62 (68.1%) 38 (65.5%) 100 (67.1%)
 Inpatient 29 (31.9%) 20 (34.5%) 49 (32.9%)
Patient Category
 New 52 (57.1%) 38 (65.5%) 90 (60.4%)
 Previously treated 23 (25.3%) 13 (22.4%) 36 (24.2%)
 Missing 16 (17.6%) 7 (12.1%) 23 (15.4%)
TB Type
 PTB and EPTB or EPTB only 14 (15.4%) 10 (17.2%) 24 (16.1%)
 PTB and not reported 77 (84.6%) 48 (82.8%) 125 (83.9%)
Smear Microscopy
 Negative 57 (62.6%) 42 (72.4%) 99 (66.4%)
 Positive 17 (18.7%) 9 (15.5%) 26 (17.4%)
 Unknown 17 (18.7%) 7 (12.1%) 24 (16.1%)
  1. PTB pulmonary tuberculosis, EPTB extra pulmonary tuberculosis, DR-TB drug-resistant TB, MDR-TB multi-drug resistant TB, RR-TB rifampicin-resistant tuberculosis, RIF rifampicin, INH isoniazid, Hb hemoglobin
  2. # Among patients who are HIV positive (n = 116)
  3. & Among patients who are HIV positive and on ART (n = 94)
  4. a Standard long-course = 6 months of injectable kanamycin and 18–24 months of oral moxifloxacin, ethionamide, terizidone, and pyrazinamide
  5. b Individualized long-course = bedaquiline was introduced as a substitute for kanamycin in the standard long-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)
  6. c Standard short-course = 4 to 6-month intensive phase of kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide and high-dose isoniazid followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol
  7. d Individualized short-course = bedaquiline was introduced as a substitute for kanamycin in the standard short-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)